Claudio Laudani/X
Aug 8, 2025, 15:28
Claudio Laudani: New Insights on P2Y12 Monotherapy in Antiplatelet Therapy
Claudio Laudani, Cardiovascular Disease Fellow UNICT, Post-Doc Research Scholar UFHealth JAX, shared a post on X:
”The landscape of antiplatelets has changed in the last decade, shifting from the initial focus on long-term DAPT to P2Y12 inhibitor monotherapy. In this review, we summarize the pharmacology and clinical evidence on antiplatelet montherapy.”
Read the full article here.
Title: Antiplatelet Monotherapies for Long-Term Secondary Prevention Following Percutaneous Coronary Intervention
Authors: Claudio Laudani, Daniele Giacoppo, Antonio Greco, Luis Ortega-Paz, Georges El Khoury, Davide Capodanno, Dominick J. Angiolillo
Stay updated with Hemostasis Today.
-
Jan 9, 2026, 06:25Sara Ng: VTE Continues to Plague Modern Oncology
-
Jan 9, 2026, 06:12James Caldwell on The Hidden Culprit in Perimesencephalic SAH
-
Jan 8, 2026, 05:51Dominika Jędrzejewska Akbaş Links Sleep Deprivation, Obesity, and Stroke
-
Jan 8, 2026, 05:42Rob Maloney: A Bruise that Did Not Go Away…
-
Jan 8, 2026, 05:33Matías J Alet on Treating Early Neurological Deterioration in Lacunar Stroke
-
Jan 8, 2026, 05:11Thomas Meinel Shares The English Stroke Guidelines 2026
-
Jan 8, 2026, 05:03Hilla Ben-Pazi: We Were Pleased to Receive a Grant from the Israeli Ministry of Economy
-
Jan 8, 2026, 04:24Nikhil Agrawal Breaks Down Perioperative Anticoagulation
-
Jan 8, 2026, 03:58Louise St Germain Bannon Appointed Interim Executive Director of ISTH